- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03084250
The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
The CHB subjects who are cirrhosis, will be randomized to two groups.
The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, randomized, open-label study.
The CHB subjects who are cirrhosis will be randomized to two groups.
The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Nanhua Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients with age ≥18 and ≤65 years;
- There should be evidences that HBsAg has been positive for more than 6 months with HBsAb and HBeAb negative; HBV-related cirrhosis
- Women without ongoing pregnancy or breast feeding and both women and men willing to take an effective contraceptive measure during the treatment;
- Agree to participate in the study and sign the patient informed consent form.
Exclusion Criteria:
- Treated by immunosuppressant,immunomodulator,Systemic cytotoxic drug,herbs or HBIg within 6 months prior to the first dose of treatment;
- ALT≥10 X ULN or total bilirubin ≥2 X ULN;
- Allergic history to interferon;
- Co-infection with active hepatitis A, hepatitis C, hepatitis D and/or human immunodeficiency virus (HIV);
- Child-Pugh scores >7;
- History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures, thalassemia);
- Pregnant or breast-feeding Women;
- Consuming alcohol in excess of 20g/day for women and 30g/day for men within 6 months prior to enrollment or drug taking history;
- ANC(absolute neutrophil count)<1.5x 10^9/L or PLT(platelet count)<90x 10^9/L
- Creatinine over upper limit of normal;
- History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as major depression or psychosis that treated with antidepressant medication or a major tranquilizer at therapeutic doses respectively at any time prior to 3 months or any history of the following: a suicidal attempt hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease;
- History of immunologically mediated disease, (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis etc.);
- History of esophageal varices bleeding or other evidence of esophageal varices bleeding or other symptoms consistent with decompensated liver disease;
- History of severe cardiac disease (e.g., New York Heart Association Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases);
- Hemodialysis patients or patients with renal insufficiency;
- History of a severe seizure disorder or current anticonvulsant use;
- Major organ transplantation or other evidence of severe illness, malignancy, or any other conditions, which would make the patient, in the opinion of the investigator, unsuitable for the study;
- History of thyroid disease poorly controlled on prescribed medications;
- Evidence of severe retinopathy or clinically relevant ophthalmologic disorder;
- History of other severe disease or evidence of other severe disease or any other illness or conditions that the investigator believe that patients are not suitable to join in the study;
- Patients included in another trial or having been given investigational drugs within 12 weeks prior to screening;
- AFP(alpha feto protein)>50ng/ml and/or evidence of hepatocellular carcinoma;
- Patients treated with Telbivudine;
- Other disease should exclusive considered by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combination
The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a
|
180μg/week, 48 weeks; 135μg/week,48weeks
Other Names:
|
Active Comparator: nucleotide analogue
The subjects will be treated by nucleotide analogue (NA) only
|
Adefovir, entecavir,tenofovir, either of them is ok
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects who develop to hepatocellular carcinoma during 5 years
Time Frame: 5 years
|
The number of subjects develop to hepatocellular carcinoma during 5 years will be measured
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants who achieve HBeAg loss and HBeAg seroconversion
Time Frame: year 1,2,3,4,5
|
The number of subjects with HBeAg loss and HBeAg seroconversion at year 1 ,2,3,4 and 5 will be measured
|
year 1,2,3,4,5
|
Number of participants who achieve HBsAg loss and HBsAg seroconversion
Time Frame: year 1,2,3,4,5
|
The number of subjects with HBsAg loss and HBsAg seroconversion at year 1, 2,3,4 and 5 will be measured
|
year 1,2,3,4,5
|
The factor such as HBsAg level related to the incidence of HCC development
Time Frame: year 1
|
The HBsAg level at year 1 will be measured, to assess whether the quantitative HBsAg level related to the incidence of HCC development
|
year 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chenbo Hu, Nanhua Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Hepadnaviridae Infections
- DNA Virus Infections
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, Chronic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Tenofovir
- Peginterferon alfa-2a
- Entecavir
- Adefovir
Other Study ID Numbers
- High risk of HCC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis B
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Gilead SciencesNot yet recruiting
-
Ain Shams UniversityCompleted
-
National Taiwan University HospitalChiayi Christian Hospital; E-DA Hospital; Taipei City Hospital; Taipei Tzu Chi... and other collaboratorsRecruitingChronic Hepatitis b | Hepatitis B ReactivationTaiwan
-
Mahidol UniversityUnknownChronic Hepatitis B, HBsAg, Hepatitis B VaccineThailand
-
Nanfang Hospital of Southern Medical UniversityRecruiting
-
IlDong Pharmaceutical Co LtdRecruitingChronic Hepatitis bKorea, Republic of
-
Antios Therapeutics, IncTerminatedChronic Hepatitis bUnited States
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruitingChronic Hepatitis b | Cirrhosis Due to Hepatitis BChina
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownChronic Hepatitis b
Clinical Trials on Peginterferon Alfa-2A
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; Huazhong University of Science and Technology; First People... and other collaboratorsUnknown
-
Third Affiliated Hospital, Sun Yat-Sen UniversityPeking University; Huazhong University of Science and Technology; First People... and other collaboratorsUnknownChronic Hepatitis BChina
-
Hoffmann-La RocheCompleted
-
Xiamen Amoytop Biotech Co., Ltd.Peking University First HospitalCompleted
-
Hoffmann-La RocheCompletedHepatitis C, ChronicRussian Federation
-
Chugai PharmaceuticalCompleted
-
The Second Affiliated Hospital of Chongqing Medical...Unknown
-
Hoffmann-La RocheCompletedHepatitis B, ChronicRussian Federation
-
Hoffmann-La RocheCompletedHepatitis B, ChronicTaiwan, United States, New Zealand, Singapore
-
Hoffmann-La RocheCompletedHepatitis C, ChronicBelgium, Ireland, Italy, United Kingdom